Global Intestine Cancer Therapeutics Market, By Treatment Type (Immunotherapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Intestine Cancer Therapeutics Market Analysis and Size
The global intestine cancer therapeutics market is expected to witness significant growth during the forecast period. Intestine cancer accounted for around 8.0% of the global cancer prevalence in 2016, making it the third most common cancer type, following lung and breast cancer. The endlessly improving healthcare infrastructure and the rise in people's disposable incomes in Asia-Pacific region are expected to increase the market in the forecast period. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global intestine cancer therapeutics market in the forecast period 2022-2029. The expected CAGR of global intestine cancer therapeutics market is tend to be around 8.10% in the mentioned forecast period. The market was valued at USD 11.70 billion in 2021, and it would grow upto USD 21.82 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Intestine Cancer Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Immunotherapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
Intestine cancer is a rare type of malignant cancer where the tumors develop from cells in the small intestine tissue that results in the blockage in the flow of food and affect digestion. The typical symptoms of intestine cancer are weight loss, extreme tiredness, excruciating pain in abdomens, and many others. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Intestine Cancer Therapeutics Market Dynamics
Drivers
- Increase in Intestine Cancer
Numerous environmental and genetic factors may increase the risk of developing the disease. According to the American Cancer Society records, around 1 in 23 women and 1 in 21 men in U.S. are projected to develop intestine cancer during their lifetime. Nonetheless, intestine cancer has decreased over the last few years because of the advanced screening and diagnostics as well as improved treatments. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global intestine cancer therapeutics market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rising Adoption of Biosimilars
Several key products such as Avastin, Vectibix, and Zaltrap are projected to lose patent exclusivities during the forecast period. These patent expirations will encourage the penetration of biosimilars. For instance, Amgen and Allergan’s Mvasi was the first biosimilar to Avastin that was approved in U.S. and Europe, thus marking the entry of biosimilars into the field of oncology. Several other bevacizumab and cetuximab biosimilars are under process and are most likely to affect branded sales when launched.
- Higher Indulgence of Immunotherapy
The segment of immunotherapy is projected to gain further attraction during the forecast period. Immunotherapeutics tend to have less adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are most likely to suppress the growth of chemotherapeutics and boost the adoption of immunotherapeutics and other targeted treatments. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global intestine cancer therapeutics market over a forecast period.
- High Cost
The huge expenditure of the treatment methods such as immunotherapy, chemotherapy, medications are surely hamper the market growth.
This global intestine cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global intestine cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Intestine Cancer Therapeutics Market
The current pandemic of Covid-19 has made a major impact on every business. The healthcare industry was facing shortage of medical aid as there were not enough beds to suffice the needs of the increasing number of patients. The world economy is fluctuating as most businesses are at a halt and the ones running from the vicinity of their homes are barely able to manage revenue. A major effect of the COVID-19 pandemic has been a delay in the treatment of intestine cancer, which can have harmful consequences for the overall and disease-free survival of patients. With the decline in COVID-19 cases, the number of referrals for intestine cancer treatment has reduced significantly.
Global Intestine Cancer Therapeutics Market Scope
The global intestine cancer therapeutics market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Immunotherapy
- Chemotherapy
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Intestine Cancer Therapeutics Market Regional Analysis/Insights
The global intestine cancer therapeutics market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global intestine cancer therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increase prevalence of intestine cancer and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Intestine Cancer Therapeutics Market Share Analysis
The global intestine cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global intestine cancer therapeutics market.
Key players operating in the global intestine cancer therapeutics market include:
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
SKU-